Emergence of MRSA in positive blood cultures from patients with febrile neutropenia—a cause for concern
- First Online:
Goals of work
Febrile neutropenia (FN) causes considerable morbidity in patients on cytotoxic chemotherapy. Recently, there has been a trend towards fewer Gram-negative and more Gram-positive infections with increasing antibiotic resistance. To assess these patterns, data from a supra-regional cancer centre in Ireland were reviewed.
Patients and methods
A 5-year review of all positive blood cultures in patients undergoing anti-cancer chemotherapy was carried out.
Eight hundred and ninety-four patients were reviewed. The mean incidence of FN was 64.2 cases per year. Eight hundred and forty-six blood culture specimens were taken and 173 (20.4%) were culture positive. The isolated organisms were Gram positive (71.1%), Gram negative (27.8%) and fungal (1.1%). Of the Gram-positive organisms, 75.6% were staphylococci. Of these, 67.8% were coagulase-negative staphylococci and 30.1% were Staphylococci aureus. Amongst the S. aureus, 89.3% were methicillin-resistant (MRSA). Vancomycin-resistant enterococci were not identified as a cause of positive blood cultures.
Amongst patients with cancer who develop FN in our hospital, Gram-positive bacteria account for the largest proportion. The high proportion of MRSA as a cause of positive blood cultures is of concern.
KeywordsFebrile neutropenia MRSA VRE Blood cultures
methicillin-resistant Staphylococcus aureus
- S. aureus
- 3.Klastersky J, Aoun M (2004) Opportunistic infections in patients with cancer. Ann Oncol 15:329–335Google Scholar
- 12.Reynolds R, Potz N, Colman M et al (2004) BSAC extended working party on bacteraemia resistance surveillance. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 53:1018–1032PubMedCrossRefGoogle Scholar
- 13.Irish European Antimicrobial Resistance Surveillance System Steering Group (EARSS) EARSS Report for Quarter 1 2007 (Ireland). Health Services Executive, Health Protection Surveillance Centre, Dublin, http://www.ndsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/EARSSSurveillanceReports/2007Reports/
- 16.National Cancer Institute (2003) Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute, Bethesda, www.cancer.gov
- 18.Paul M, Borok S, Fraser A et al (2005) Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev (3) Art. No.: CD003914. DOI 10.1002/14651858.CD003914.pub2